Arbekacin postmarketing clinical study

Keisuke Sunakawa, Hiroshi Sakata, Yoshitake Sato, Itaru Terashima, Kouya Shiba, Satoshi Iwata, Hironobu Akita, Tetsuo Yokoyama, Hiroyuki Shiro, Ayumu Sunaoshi, Syunkichi Baba, Naoichi Iwai, Kazunobu Ouchi, Takashi Motohiro, Naoki Tsumura, Nobuo Sato, Shigeki Shibasaki

Research output: Contribution to journalArticle

Abstract

We conducted a multicenter postmarketing clinical study to obtain arbekacin sulfate (ABK) pharmacokinetic parameters in children younger than 6 years, with the following results: Patients were divided into group A; neonates and low-birth-weight (LBW) infants (n=7) and group B; infants and children (n=3). A dose of 2-3 mg/kg of ABK was administered intravenously by infusion for 30 min, and pharmacokinetic parameters were obtained. Two LBW infants and one neonate were excluded because of infusion errors and administration of a steroid drug that may affect ABK efficacy. Maximum plasma concentrations (Cmax) were 6.64±1.13 (μg/mL) for group A (n=4) and 7.91±1.43 (μg/mL) for group B (n=3), indicating no significant difference (p=0.2429). Steady-state volume of distributions (Vdss) were 0.382±0.045 (L/kg) and 0.304±0.060 (L/kg), and plasma half-lives (t1/2) 3.20±0.91 (h) and 1.73 ±0.43 (h) for groups A and B. Although these were not significant different between groups (p=0.1049 and 0.0515), group A means were larger. Total body clearance (Cltot) was 0.091±0.017 (L/h/kg) and 0.154 ±0.030 (L/h/kg) for groups A and B. The group B mean was significantly larger (p=0.0148). Predicted plasma concentrations 12 h after infusion (trough), calculated ABK pharmacokinetic parameters, were 0.42±0.25 (μg/mL) for groups A and B. ABK plasma concentration profiles of these children were similar to those of adults, which were recommended in consideration of clinical effects and safety.

Original languageEnglish
Pages (from-to)91-96
Number of pages6
JournalJapanese Journal of Chemotherapy
Volume51
Issue number2
Publication statusPublished - 2003 Feb 1
Externally publishedYes

Fingerprint

Pharmacokinetics
Low Birth Weight Infant
Newborn Infant
Steroids
habekacin
Clinical Studies
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Sunakawa, K., Sakata, H., Sato, Y., Terashima, I., Shiba, K., Iwata, S., ... Shibasaki, S. (2003). Arbekacin postmarketing clinical study. Japanese Journal of Chemotherapy, 51(2), 91-96.

Arbekacin postmarketing clinical study. / Sunakawa, Keisuke; Sakata, Hiroshi; Sato, Yoshitake; Terashima, Itaru; Shiba, Kouya; Iwata, Satoshi; Akita, Hironobu; Yokoyama, Tetsuo; Shiro, Hiroyuki; Sunaoshi, Ayumu; Baba, Syunkichi; Iwai, Naoichi; Ouchi, Kazunobu; Motohiro, Takashi; Tsumura, Naoki; Sato, Nobuo; Shibasaki, Shigeki.

In: Japanese Journal of Chemotherapy, Vol. 51, No. 2, 01.02.2003, p. 91-96.

Research output: Contribution to journalArticle

Sunakawa, K, Sakata, H, Sato, Y, Terashima, I, Shiba, K, Iwata, S, Akita, H, Yokoyama, T, Shiro, H, Sunaoshi, A, Baba, S, Iwai, N, Ouchi, K, Motohiro, T, Tsumura, N, Sato, N & Shibasaki, S 2003, 'Arbekacin postmarketing clinical study', Japanese Journal of Chemotherapy, vol. 51, no. 2, pp. 91-96.
Sunakawa K, Sakata H, Sato Y, Terashima I, Shiba K, Iwata S et al. Arbekacin postmarketing clinical study. Japanese Journal of Chemotherapy. 2003 Feb 1;51(2):91-96.
Sunakawa, Keisuke ; Sakata, Hiroshi ; Sato, Yoshitake ; Terashima, Itaru ; Shiba, Kouya ; Iwata, Satoshi ; Akita, Hironobu ; Yokoyama, Tetsuo ; Shiro, Hiroyuki ; Sunaoshi, Ayumu ; Baba, Syunkichi ; Iwai, Naoichi ; Ouchi, Kazunobu ; Motohiro, Takashi ; Tsumura, Naoki ; Sato, Nobuo ; Shibasaki, Shigeki. / Arbekacin postmarketing clinical study. In: Japanese Journal of Chemotherapy. 2003 ; Vol. 51, No. 2. pp. 91-96.
@article{263aea8b18b145d9bcddb9d025d593ea,
title = "Arbekacin postmarketing clinical study",
abstract = "We conducted a multicenter postmarketing clinical study to obtain arbekacin sulfate (ABK) pharmacokinetic parameters in children younger than 6 years, with the following results: Patients were divided into group A; neonates and low-birth-weight (LBW) infants (n=7) and group B; infants and children (n=3). A dose of 2-3 mg/kg of ABK was administered intravenously by infusion for 30 min, and pharmacokinetic parameters were obtained. Two LBW infants and one neonate were excluded because of infusion errors and administration of a steroid drug that may affect ABK efficacy. Maximum plasma concentrations (Cmax) were 6.64±1.13 (μg/mL) for group A (n=4) and 7.91±1.43 (μg/mL) for group B (n=3), indicating no significant difference (p=0.2429). Steady-state volume of distributions (Vdss) were 0.382±0.045 (L/kg) and 0.304±0.060 (L/kg), and plasma half-lives (t1/2) 3.20±0.91 (h) and 1.73 ±0.43 (h) for groups A and B. Although these were not significant different between groups (p=0.1049 and 0.0515), group A means were larger. Total body clearance (Cltot) was 0.091±0.017 (L/h/kg) and 0.154 ±0.030 (L/h/kg) for groups A and B. The group B mean was significantly larger (p=0.0148). Predicted plasma concentrations 12 h after infusion (trough), calculated ABK pharmacokinetic parameters, were 0.42±0.25 (μg/mL) for groups A and B. ABK plasma concentration profiles of these children were similar to those of adults, which were recommended in consideration of clinical effects and safety.",
author = "Keisuke Sunakawa and Hiroshi Sakata and Yoshitake Sato and Itaru Terashima and Kouya Shiba and Satoshi Iwata and Hironobu Akita and Tetsuo Yokoyama and Hiroyuki Shiro and Ayumu Sunaoshi and Syunkichi Baba and Naoichi Iwai and Kazunobu Ouchi and Takashi Motohiro and Naoki Tsumura and Nobuo Sato and Shigeki Shibasaki",
year = "2003",
month = "2",
day = "1",
language = "English",
volume = "51",
pages = "91--96",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "2",

}

TY - JOUR

T1 - Arbekacin postmarketing clinical study

AU - Sunakawa, Keisuke

AU - Sakata, Hiroshi

AU - Sato, Yoshitake

AU - Terashima, Itaru

AU - Shiba, Kouya

AU - Iwata, Satoshi

AU - Akita, Hironobu

AU - Yokoyama, Tetsuo

AU - Shiro, Hiroyuki

AU - Sunaoshi, Ayumu

AU - Baba, Syunkichi

AU - Iwai, Naoichi

AU - Ouchi, Kazunobu

AU - Motohiro, Takashi

AU - Tsumura, Naoki

AU - Sato, Nobuo

AU - Shibasaki, Shigeki

PY - 2003/2/1

Y1 - 2003/2/1

N2 - We conducted a multicenter postmarketing clinical study to obtain arbekacin sulfate (ABK) pharmacokinetic parameters in children younger than 6 years, with the following results: Patients were divided into group A; neonates and low-birth-weight (LBW) infants (n=7) and group B; infants and children (n=3). A dose of 2-3 mg/kg of ABK was administered intravenously by infusion for 30 min, and pharmacokinetic parameters were obtained. Two LBW infants and one neonate were excluded because of infusion errors and administration of a steroid drug that may affect ABK efficacy. Maximum plasma concentrations (Cmax) were 6.64±1.13 (μg/mL) for group A (n=4) and 7.91±1.43 (μg/mL) for group B (n=3), indicating no significant difference (p=0.2429). Steady-state volume of distributions (Vdss) were 0.382±0.045 (L/kg) and 0.304±0.060 (L/kg), and plasma half-lives (t1/2) 3.20±0.91 (h) and 1.73 ±0.43 (h) for groups A and B. Although these were not significant different between groups (p=0.1049 and 0.0515), group A means were larger. Total body clearance (Cltot) was 0.091±0.017 (L/h/kg) and 0.154 ±0.030 (L/h/kg) for groups A and B. The group B mean was significantly larger (p=0.0148). Predicted plasma concentrations 12 h after infusion (trough), calculated ABK pharmacokinetic parameters, were 0.42±0.25 (μg/mL) for groups A and B. ABK plasma concentration profiles of these children were similar to those of adults, which were recommended in consideration of clinical effects and safety.

AB - We conducted a multicenter postmarketing clinical study to obtain arbekacin sulfate (ABK) pharmacokinetic parameters in children younger than 6 years, with the following results: Patients were divided into group A; neonates and low-birth-weight (LBW) infants (n=7) and group B; infants and children (n=3). A dose of 2-3 mg/kg of ABK was administered intravenously by infusion for 30 min, and pharmacokinetic parameters were obtained. Two LBW infants and one neonate were excluded because of infusion errors and administration of a steroid drug that may affect ABK efficacy. Maximum plasma concentrations (Cmax) were 6.64±1.13 (μg/mL) for group A (n=4) and 7.91±1.43 (μg/mL) for group B (n=3), indicating no significant difference (p=0.2429). Steady-state volume of distributions (Vdss) were 0.382±0.045 (L/kg) and 0.304±0.060 (L/kg), and plasma half-lives (t1/2) 3.20±0.91 (h) and 1.73 ±0.43 (h) for groups A and B. Although these were not significant different between groups (p=0.1049 and 0.0515), group A means were larger. Total body clearance (Cltot) was 0.091±0.017 (L/h/kg) and 0.154 ±0.030 (L/h/kg) for groups A and B. The group B mean was significantly larger (p=0.0148). Predicted plasma concentrations 12 h after infusion (trough), calculated ABK pharmacokinetic parameters, were 0.42±0.25 (μg/mL) for groups A and B. ABK plasma concentration profiles of these children were similar to those of adults, which were recommended in consideration of clinical effects and safety.

UR - http://www.scopus.com/inward/record.url?scp=0037299255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037299255&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0037299255

VL - 51

SP - 91

EP - 96

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 2

ER -